Regenovue Plus Regulatory Status: An Essential Guide for Aesthetic Professionals

Regenovue Plus is a hyaluronic acid dermal filler manufactured by NeoGenesis Co., Ltd., originating from South Korea. It is formulated for specific aesthetic applications, offering professionals an option within the diverse Hyaluronic acid dermal filler catalog. As with any injectable product, its market acceptance and professional use depend directly on its adherence to regional health and safety standards.

The regulatory landscape for medical devices like dermal fillers varies globally. For products originating from South Korea, Korean Food and Drug Administration (KFDA) approval is a foundational certification. This indicates compliance with national manufacturing and safety standards. Beyond this, international market access depends on specific regional certifications:

• KFDA Approval: As a South Korean product, Regenovue Plus is expected to hold KFDA certification, affirming its manufacturing quality and safety for the domestic market.
• CE Mark Status: For distribution within the European Union and certain other markets, a CE Mark is required. [VERIFY: Regenovue Plus CE Mark status for current approval and classification].
• FDA Clearance: Obtaining clearance from the U.S. Food and Drug Administration (FDA) is a rigorous process for dermal fillers. [VERIFY: Regenovue Plus FDA clearance status]. Most Korean dermal fillers do not possess full FDA approval for direct market entry into the United States.
• GMP & ISO Standards: Manufacturing facilities typically adhere to Good Manufacturing Practices (GMP) and ISO standards (e.g., ISO 13485 for medical devices), ensuring consistent quality control and traceability. Professionals should confirm that their suppliers can provide documentation of these standards for the manufacturer.

The ability to legally source and utilize Regenovue Plus depends on its regulatory standing in different geographic areas:

• European Union (EU) & UK: Market access is contingent on the product holding a valid CE Mark, ensuring compliance with EU medical device regulations. For insights into other filler regulatory pathways, refer to our guide on StarFill Regulatory Status.
• GCC Countries (Gulf Cooperation Council): Regulations often align with EU or US standards, requiring product registration with local health authorities, often based on existing CE or specific national approvals. [VERIFY: specific country registrations for Regenovue Plus in UAE, Saudi Arabia, etc.].
• LATAM (Latin America): Regulatory requirements are diverse across Central and South American nations. Many countries accept CE marking as part of their national registration process, while others demand independent local registration. Professionals should consult their national health ministries for specifics.
• APAC (Asia-Pacific): Beyond KFDA, market access in countries like Australia, Singapore, or Thailand requires compliance with their respective national regulatory bodies, which may involve additional documentation or local clinical data.

When sourcing Regenovue Plus, professionals must prioritize authenticity. The market for aesthetic injectables can involve unauthorized parallel imports, which may not adhere to proper storage or supply chain integrity. Always demand proof of legitimate origin and quality documentation. This ensures product integrity and patient safety for your clinic. Similar considerations apply to other popular fillers, as detailed in our analysis of Yvoire Volume Plus Regulatory Status.

Understanding the regulatory status complements sound procurement practices. Regenovue Plus is available to professionals at a wholesale price of approximately $75.8 per unit. Volume-based tiers offer incremental savings:

This tiered structure allows clinics to optimize their stock of essential aesthetic injectables, including other popular options like D.Fill Medium or Hyaldew, by balancing procurement volume with cost efficiency while ensuring regulatory compliance.